MedPage Today on MSN
Novel Complement-Targeting Agent Shows Benefit in Myasthenia Gravis
The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback